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Abstract
In 2007, the World Health Organization (WHO) received a criticism for a lack of transparency and systematic methods in the
development of guidelines, which were at that time perceived as substantially driven by expert opinion. In this paper we
assessed the quality of maternal and perinatal health guidelines developed since then. We used the Appraisal of Guidelines
for Research and Evaluation (AGREE) II tool to evaluate the quality of methodological rigour and transparency of four
different WHO guidelines published between 2007 and 2011. Our findings showed high scores among the most recent
guidelines on maternal and perinatal health suggesting higher quality. However, there is still potential for improvement,
especially in including different stakeholder views, transparency of guidelines regarding the role of the funding body and
presentation of the guideline document.
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Introduction
The World Health Organization (WHO) has an important role
in the provision of global guidance on health interventions and
health care [1]. Developing evidence-based recommendations for
a global audience enables informed decisions about clinical and
programmatic interventions, public health actions and govern-
ment policies [2]. During recent years, WHO has undergone
significant procedural changes in guideline development method-
ology.
In 2007, Oxman, Lavis and Fretheim examined the use of
evidence in WHO guidelines by interviewing senior staff. They
found infrequent use of systematic reviews, an absence of a
systematic guideline development methodology and a tendency to
rely on expert opinion [3], despite evidence of the limitations of
such an approach [4–9]. The study indicated poor internal
support for guideline development, an absence of timelines for
updating and lack of plans for dissemination and implementation
of recommendations. Harm/benefit and cost analyses were rarely
conducted or systematically reported. Guidelines were also
sometimes difficult to identify due to different labelling such as
‘technical consultation’ or ‘report of a meeting’ [3].
The WHO Guideline Review Committee (GRC) was subse-
quently established ‘‘to ensure that WHO guidelines are of a high
methodological quality and are developed through a transparent,
evidence-based decision-making process’’ [10]. The WHO guide-
line handbook was revised and standards for reporting, processes,
and evidence were established. WHO guideline development now
follows a standardized process: (i) identification of questions related
to clinical practice and health policy for which answers were
needed; (ii) retrieval of up-to-date research-based evidence; (iii)
assessment and synthesis of the evidence; (iv) formulation of
recommendations with inputs from a wide range of stakeholders;
and (v) formulation of plans for dissemination, implementation,
impact evaluation and updating [11].
The WHO Department of Reproductive Health and Research
(RHR) hosts the UNDP/UNFPA/WHO/World Bank Special
Programme of Research, Development and Research Training in
Human Reproduction (HRP). This programme is the main body
within the United Nations system for research in sexual and
reproductive health. RHR is responsible for normative guidance
on sexual and reproductive health and rights [12]. RHR published
the following maternal and perinatal health guidelines between
2007 and 2011: WHO recommendations for the prevention of
postpartum haemorrhage (2007) (herein referred to as P-PPH),
WHO guidelines for the management of PPH and retained
placenta (2009, M-PPH), WHO recommendations for induction of
labour (2011, IOL) and WHO recommendations for prevention
and treatment of pre-eclampsia and eclampsia (2011, PE/E) [13–
16]. The P-PPH guideline precedes the establishment of the WHO
Guidelines Review Committee (GRC) and laid the foundation for
the standards that followed [17].
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This analysis aimed to assess the quality of maternal and
perinatal health guideline development by examining the four
guidelines described above. We used the Appraisal of Guidelines
for Research and Evaluation (AGREE) II tool to evaluate each
guideline [18]. The AGREE II tool is a widely-used instrument to
assess methodological rigour and transparency of guideline
development and has been tested for its validity and reliability.
It uses a detailed framework to assess guideline quality, but also
provides a methodological strategy for guideline development and
content [18,19]. The AGREE tool was recently used by the
Reproductive Health Library (RHL) at WHO to appraise the
quality of the P-PPH, M-PPH and IOL guidelines in a separate
analysis. RHL engaged independent, external commentators with
a strong obstetric background to conduct those appraisals [20].
Methods
Four appraisers who had not previously participated in the
development of WHO guidelines conducted the assessment (SP,
PL, JV, KW). The appraisers used the online training tools
recommended by the AGREE collaboration before conducting
appraisals. Each of the four guidelines was rated independently
with the AGREE II tool online by each appraiser. Appraisers did
not communicate or confer with each other during the appraisal
process.
The AGREE II tool encompasses 23 items in six domains: scope
and purpose (3 items), stakeholder involvement (3 items), rigour of
development (8 items), clarity of presentation (3 items), applica-
bility (4 items), and editorial independence (2 items). The domain
scope and purpose assesses whether the guideline describes its overall
objective and target population clearly. A guideline should entail a
clear definition of the target users, as well as demonstrate that the
views and preferences of the target population (e.g. patients,
public) have been sought and that the guideline development
group includes all relevant professional groups which is assessed in
stakeholder improvement. The next domain assesses the rigour of
guideline development, encompassing systematic literature search-
ing methodology, transparency of evidence-gathering process and
whether evidence is explicitly linked to the recommendations. It
also asks if the guideline has been externally reviewed prior to
publication and if an updating strategy has been documented. The
fourth domain examines clarity of guideline presentation.
Recommendations must be specific, unambiguous and easily
identifiable. Different options for management of the condition or
health issue should be clearly presented. Applicability examines
whether guidelines describe facilitators and barriers to application
and if they provide advice and/or tools on how the recommen-
dations can be put into practice. It also assesses resource
implications for guideline application and monitoring and/or
auditing criteria [18]. Transparency of guideline funding bodies
and conflicts of interest were examined in editorial independence [18].
Each item is rated from 1 (strongly disagree) to 7 (strongly
agree). Detailed criteria for each item are available within the
AGREE II tool to assist the appraiser [18]. The appraisers were
asked to provide comments to justify their rating. They also gave
an overall assessment of the guideline from 1 (lowest) to 7 (highest)
and were asked to state if they would recommend the guideline,
recommend it with modifications or not recommend it.
Average appraisal scores were calculated for each appraiser by
taking the average rating (1–7) for all items of a single guideline.
From this, overall average appraisal scores and standard deviations
were calculated for all four appraisers for a single guideline. Scaled
percentages for each domain were then calculated for inter-
domain comparison. This was done by adding all four appraiser
ratings (1–7) of items within a single domain (obtained score) and
scaling by maximum and minimum possible domain scores and
converting to a percentage.
E.g.:
Obtained score~
sum of all item scores for all appraisers in a single domain
Maximum possible score~
7 strongly agreeð Þ|y items within domainð Þ|4 appraisersð Þ
Minimum possible score~
1 strongly disagreeð Þ|y items within domainð Þ|4 appraisersð Þ
Scaled domain score~
Obtained score{Minimum possible scoreð Þ
Maximum possible score{Minimum possible scoreð Þ|100
The raw appraisal scores in all four guidelines were tabulated in
Microsoft Excel (Washington, USA) and sent to the appraisers for
review and detection of potential rating errors. Appraisers were
permitted to modify their ratings if errors were detected. Final
average appraisal scores and standard deviations for each domain
and scaled domain percentages were calculated. The results were
shared anonymously among the authors.
Results
Average appraisal scores and average overall assessments for
each guideline are shown in Table 1. When arranged chronolog-
ically, the average overall assessment score of the quality of
recommendations tended to increase over time: P-PPH 4.3 (SD:
1.0), M-PPH 5.3 (SD: 1.0), IOL 6.0 (SD: 0.0) and PE/E 6.3 (SD:
0.5). We found that the overall assessment averages were
consistently higher than the average scores calculated from the
individual items. All appraisers recommended the P-PPH with
modifications, three recommended the M-PPH guideline with
modifications and three recommended the IOL guideline without
modifications. All four appraisers recommended the PE/E without
modification (Table 2).
Table 3 presents the scaled domain percentages for all four
guidelines. Concerning scope and purpose of the guidelines, the recent
guidelines scored highest, though since 2007 the scores were
relatively high (79%). Stakeholder involvement was rated higher over
time - P-PPH (2007) scored 32%, M-PPH (2009) 51%, IOL (2011)
69% and PE/E (2011) 86%. Rigour of Development scores tended to
be higher in the recent guidelines, although scores were relatively
high in all four guidelines. Clarity of Presentation scored over 90% in
the IOL and PE/E guidelines. The appraisers gave relatively low
scores on applicability throughout all four guidelines, although the
P-PPH from 2007 scored the lowest with 22%, followed by M-
PPH, scoring 29% and IOL and PE/E scoring 61% and 58%,
respectively. Editorial independence has the most variation in scores as
presented in the table. The complete assessments of all four
appraisers are presented in Tables S1, S2, S3, S4, S5, S6, S7 and
S8.
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Discussion
We used the AGREE II online guideline assessment tool to
evaluate the quality of four WHO reproductive health guidelines
issued between 2007 and 2011 [13–16]. The AGREE II tool
assesses several guideline domains and evaluates their quality using
numeric scores (higher scores suggest a higher quality of the
respective domain) (REF). In general, the two most recent
guidelines (2011) tended to receive higher AGREE II scores as
compared to the guidelines issued in 2007 and 2009. This may
suggest an improvement in the quality of those guidelines
according to the AGREE methods.
It should be noted that among the six domains evaluated by the
AGREE II tool, three of them (Scope and purpose, rigour of
development and clarity of presentation) had received scores in the
higher end of the spectrum of quality in all four guidelines. This
may be due to the fact that the WHO Department of
Reproductive Health and Research is recognized as having a
very strong methodological component and a large experience in
randomized trials and systematic reviews.
However, the involvement of stakeholders, particularly the
integration of the ‘‘views and preferences of the target population’’,
remains a challenge. RHL commentators conducting independent
assessments of these guidelines have also identified this as a
weakness of some of these guidelines [21]. The WHO Guideline
Review Committee suggests that the views of end-users and
patients are considered during the development of WHO
Guidelines [22]. It is ethically worthwhile to include consumer
representation in the development process and to acknowledge
their views and values where possible. Nevertheless, although
desirable, consumer representation and engagement may be not
straightforward in guidelines (such the ones produced by WHO)
that target many diverse settings in low and middle-income
countries.
The appraisers identified clarity and visibility of key recom-
mendations as strengths of the IOL and PE/E guidelines.
However, appraisers suggested that presenting the guideline in
two versions would be of benefit: one containing a detailed
description of methodology and evidence, and a simpler version
with key messages only. This would allow target users to capture
the key recommendations easily, improving compliance with best
practice.
Applicability and editorial independence were the lowest scoring
domains in the two most recent guidelines. The low scores in the
applicability domain (61% and 58% for IOL and PE/E respectively)
reflect poor scoring in items on resource implications and cost
effectiveness. However, WHO guidelines target a wide variety of
countries, making specific and detailed information about
resources and financial costs problematic. The RHL commenta-
tors drew similar conclusions for the IOL guideline, remarking
that while no cost analysis was conducted, the recommendations
are ‘‘feasible in under-resourced settings’’ and ‘‘likely to be cost–
effective and acceptable to the pregnant women, their obstetricians
and policy-makers in under-resourced settings’’ [21]. Whether
economic assessments are necessary or feasible for global
guidelines might indicate a contextuality issue in applying the
AGREE II tool to WHO guidelines.
In spite of the fact that the funding bodies of these four
guidelines are essentially governmental agencies and academic
institutions (without commercial interests in the content of the
recommendations), appraisers noted that additional details on the
role of the funding bodies in the content of the guideline would be of
benefit. Disclosure of funding sources and influence contributes to
Table 1. Total score averages and overall assessment averages for all four guidelines from the AGREE II tool appraisals.
Guideline Appraiser 1 Appraiser 2 Appraiser 3 Appraiser 4 Average* SD
P-PPH (2007) Average 3.3 4.5 4.6 3.8 4.1 0.6
Overall assessment 3.0 5.0 5.0 4.0 4.3 1.0
M-PPH (2009) Average 4.2 5.5 5.3 4.6 4.9 0.6
Overall assessment 4.0 6.0 6.0 5.0 5.3 1.0
IOL (2011) Average 6.2 5.7 5.8 5.6 5.8 0.3
Overall assessment 6.0 6.0 6.0 6.0 6.0 0.0
PE/E (2011) Average 5.7 5.9 5.9 5.7 5.8 0.1
Overall assessment 6.0 6.0 7.0 6.0 6.3 0.5
*Overall average appraisal scores.
doi:10.1371/journal.pone.0038891.t001
Table 2. Appraiser recommendations for use of guidelines.
Guideline Assessor 1 Assessor 2 Assessor 3 Assessor 4
P-PPH (2007) Recommended,
with modifications
Recommended,
with modifications
Recommended,
with modifications
Recommended,
with modifications
M-PPH(2009) Recommended,
with modifications
Recommended Recommended,
with modifications
Recommended,
with modifications
IOL (2011) Recommended Recommended Recommended,
with modifications
Recommended
PE/E (2011) Recommended Recommended Recommended Recommended
doi:10.1371/journal.pone.0038891.t002
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a more transparent process and is in line with existing WHO
policy.
Oxman et al. (2007) pointed out several specific weaknesses of
the WHO guideline development process. They highlighted an
absence of systematic, transparent methods of synthesizing and
presenting evidence, as well as infrequent use of systematic reviews
and over-reliance on expert opinion [3]. Using the AGREE
methodology, the domains rigour of development and scope and purpose
had higher scores in the most recent guidelines. This may suggest
possible improvements in defining objectives and target popula-
tions as well as in systematic literature searching methodologies
and transparency of the evidence-gathering process. Oxman et al.
(2007) also identified a lack of timelines for updating and plans for
dissemination and implementation [3]. The appraisers tended to
rate higher the more recent guidelines on documented updating
strategies within the rigour of development domain. The implemen-
tation and dissemination aspects of guidelines received also higher
scores in the most recent guidelines.
There are limitations within our analysis that should be noted.
The AGREE II tool has been tested for reliability and validity, and
is applicable to a wide variety of health professionals, geographical
areas and guideline development processes [23–25]. However,
there is no threshold for discriminating ‘‘high quality’’ from ‘‘low
quality’’ guidelines, leaving appraisers to interpret scores. Thus,
the scores of an AGREE evaluation have to be interpreted with
caution and in context. Furthermore, no reliable statistical
conclusions can be drawn from a small number of appraisers
assessing guidelines in a semi-quantitative manner. In this case
study, a small number of guidelines that have been produced
sequentially over time, is evaluated. Considering the small number
of guidelines (only 4), it cannot be ruled out that the changes in the
scores are due to chance. However, it is plausible that the growing
experience of guideline development processes (particularly after
the establishment of the WHO Guideline Review Committee in
2007, which may have led to an increased awareness of quality
and transparency in the guideline development) could have
contributed to scores that tended to be higher in the most recent
guidelines.
Appraisers also remarked that if a guideline is presented in a
more structured way (without improvements in content), this
would lead to a more positive evaluation overall. Another
limitation is that the appraisers were health professionals relatively
inexperienced in guideline development and evaluation and not
blinded to the publication year of the guidelines they appraised. At
the time of appraisal they were on temporary, voluntary
assignment in RHR, which may constitute a potential conflict of
interest that needs to be considered. These factors may have
affected the quality of results and may have been a potential source
of bias. However, we tried to minimize bias ensuring adequate
training on the use of the AGREE II tool before the actual
guideline appraisal. It is worthwhile noting that the same four
appraisers assessed all four guidelines using the AGREE II tool.
Anonymisation of results and instructions to not communicate
during the appraisal process may also have contributed to
reducing the potential bias. With these actions, conditions for
effective use of the evaluating tool and a meaningful inter-
appraiser comparison were fostered. In addition, notwithstanding
having no participation in the guideline assessment, three of the
authors (JPS, MM, AMG) are WHO employees and have been
involved in the development of the guidelines under assessment.
In conclusion, the appraisals suggest that the process of
guideline development and quality of reporting are robust in
maternal and perinatal health guidelines produced by WHO.
Among the remaining challenges, the involvement of stakeholders
and the applicability aspects should be highlighted. Considering
the large number of guidelines produced by WHO, findings of this
assessment may be indicative of change, but a more comprehen-
sive assessment is needed in order to demonstrate or not a change
in the process of guideline development and the quality of
reporting in WHO.
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Table 3. Scaled domain percentages for all appraisers for each guideline.
Domain P-PPH (2007) M-PPH (2009) IOL (2011) PE/E (2011)
Scope and purpose (%) 79 68 90 89
Stakeholder involvement (%) 32 51 69 86
Rigour of development (%) 66 79 88 84
Clarity of presentation (%) 71 83 97 93
Applicability (%) 22 29 61 58
Editorial independence (%) 8 71 60 65
doi:10.1371/journal.pone.0038891.t003
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